MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.25
+0.21
+3.48%
After Hours: 6.25 0 0.00% 16:41 03/27 EDT
OPEN
5.88
PREV CLOSE
6.04
HIGH
6.36
LOW
5.58
VOLUME
324.54K
TURNOVER
--
52 WEEK HIGH
9.56
52 WEEK LOW
4.010
MARKET CAP
245.12M
P/E (TTM)
-3.3784
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NERV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NERV stock price target is 18.50 with a high estimate of 20.00 and a low estimate of 18.00.

EPS

NERV News

More
  • Edited Transcript of NERV earnings conference call or presentation 9-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
  • GlobeNewswire · 3d ago
  • Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock?
  • Zacks · 03/19 15:50
  • MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
  • GlobeNewswire · 03/12 20:15

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
More

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.